Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study

Documenti analoghi

• Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study
  di: Bar Rosh, et al.
  Pubblicazione: (2026)
• Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data
  di: Maria J. Alfonso Arvez, et al.
  Pubblicazione: (2025)
• Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain
  di: Sachalee Campbell, et al.
  Pubblicazione: (2026)
• Uncovering New Therapeutic Targets for Amyotrophic Lateral Sclerosis and Neurological Diseases Using Real‐World Data
  di: Mohammadali Alidoost, et al.
  Pubblicazione: (2025)
• Development and Validation of the Pharmacological Statin‐Associated Muscle Symptoms Risk Stratification Score Using Electronic Health Record Data
  di: Boguang Sun, et al.
  Pubblicazione: (2024)